EP3355859A1 - Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose - Google Patents

Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose

Info

Publication number
EP3355859A1
EP3355859A1 EP16775633.7A EP16775633A EP3355859A1 EP 3355859 A1 EP3355859 A1 EP 3355859A1 EP 16775633 A EP16775633 A EP 16775633A EP 3355859 A1 EP3355859 A1 EP 3355859A1
Authority
EP
European Patent Office
Prior art keywords
composition
agents
composition according
weight
generating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16775633.7A
Other languages
German (de)
English (en)
French (fr)
Inventor
Jean-Christophe Buge
Karine Nadau-Fourcade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP3355859A1 publication Critical patent/EP3355859A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • Non-rinsed chemical foam containing trifarotene and its use in the treatment of ichthyosis
  • the present invention relates to a topical product not rinsed in the form of a foam for the pharmaceutical or cosmetic treatment of the skin comprising trifarotene.
  • Trifarotene is a new retinoid and corresponds to 3 "-tert-butyl-4 '- (2-hydroxyethoxy) -4" -pyrrolidin-1-yl [1,1', 3 ', 1 "] terphenyl-
  • the present invention also relates to the use of the product according to the invention for the treatment of ichthyosis.
  • compositions for a more practical and fast topical application.
  • Foams help to overcome tolerance problems through better dose control, thanks to their spreading properties and low density.
  • Ichthyosis is the result of a thickening of the stratum corneum of the epidermis. They are due to the insufficient removal of the stratum corneum, or to an acceleration of the formation of the epidermis (superficial layer of the skin), and of the stratum corneum (superficial layer of the epidermis).
  • creams and ointments are indispensable in ichthyosis. These local treatments aim to reduce the dander and improve skin comfort and the appearance of the skin. These treatments include simple moisturizing creams and / or creams in which are added agents that will better detach the dander and that is called keratolytics. In all cases the treatments must bring a lot of emollience to soften the skin.
  • certain compounds used in the compositions intended for a known topical application may cause side effects which may limit their use and therefore their effectiveness.
  • some actives have the major disadvantage of inducing irritation that may result in poor tolerance of the product. This can thus create on the part of the patient a behavior of non-observance of the treatment and the discontent with regard to said treatment.
  • There is therefore a need to develop new galenic forms overcoming the aforementioned drawbacks in terms of tolerance, efficiency and compliance.
  • new galenic forms and in particular foams or foaming compositions for better dose control and in which trifarotene is stable, well tolerated, effective and pleasant to apply.
  • composition according to the invention has the advantage of being in the form of a foam generated extemporaneously, and very well tolerated.
  • composition according to the invention is not removed by rinsing.
  • composition is particularly well tolerated, even though it is not rinsed off, as shown in the examples illustrating one of the methods of assessing tolerance presented hereinafter.
  • composition also has the advantage of remaining on the surface of the skin (stratum corneum and epidermis essentially), in order to avoid undesirable effects such as irritation and to obtain a foam adapted to the treatment of ichthyosis .
  • the effectiveness of an active ingredient is related to the release and kinetics of penetration of the active through the skin.
  • the form composition plays its essential role of vehicle of the active ingredient so that it reaches its therapeutic target.
  • the release-permeation test described in Example 5 on ex-vivo human skin highlights the advantage of applying a chemical foam containing trifarotene.
  • the formulations of the invention make it possible to obtain a composition in the form of a mousse making it possible to reduce the undesirable effects and in particular the irritation, in particular on young skin.
  • the surface of the skin is also the seat of the keratolytic action of trifarotene for the treatment of ichthyosis.
  • foams or foaming compositions on the market. However, they all have a number of disadvantages:
  • Aerosols in which the foam is generated by a propellant gas but with the disadvantage of being aerosols with the risks well known to them (pollution, respiratory risks in particular).
  • Foaming formulas containing foaming surfactants generally causing irritation problems from the detergent properties of these foaming surfactants.
  • compositions for topical application containing trifarotene in well-tolerated compositions for application topically in humans particularly a non-rinsed application (i.e., the composition is not rinsed off after application).
  • the object of the present invention is therefore to provide a composition that meets these needs.
  • Foaming surfactants are defined as surfactants which produce a voluminous, stable and unctuous foam when they are mixed with water according to tests well known to those skilled in the art. Foaming surfactants include anionic surfactants, cationic surfactants, amphoteric surfactants and nonionic surfactants of the alkylpolyglucoside and glucamide family.
  • the pharmaceutical form according to the invention has the advantage of guaranteeing good stability of trifarotene.
  • this formulation advantageously leads to the production of a soft, perfectly tolerated and non-irritating foam, which allows a better coverage of the area to be treated. treat and overcomes tolerance problems through better dose control, thanks to the spreading properties and low density of the foam.
  • this dosage form does not require for its implementation the use of propellants or aerosols.
  • aerosol or spray foams are excluded from the scope of the invention.
  • foams of the prior art of expanded cream type and / or foaming formulas requiring a mechanical foam generating system are also excluded from the invention.
  • the present invention finally relates to the cosmetic use of the composition according to the invention, by topical application of this composition to the skin, and a medicament for topical application to the skin, comprising such a composition.
  • the subject of the present invention is also the composition according to the invention for its use in the treatment of ichthyosis.
  • FIG. 1 illustrates the production of a composition in the form of a foam according to the invention.
  • the photo on the left represents the moment of mixing (T0) and the photo on the right represents the foam obtained when the acid / base chemical reaction is complete.
  • FIG. 2 illustrates example 5 and represents the comparative penetration-permeation results in the stratum corneum, the epidermis and the dermis of a foam composition according to the invention at 0.04% by weight of trifarotene composed of the mixture of intermediate compositions.
  • A4 and B7 described in Example 1 in a ratio of 50/50 by weight
  • a cream reference containing 0.04% by weight of trifarotene a cream reference containing 0.04% by weight of trifarotene.
  • FIG. 3 illustrates Example 5 and represents the comparative results of penetration. permeation in the dermis of FIG. 2 on an enlarged scale.
  • composition according to the invention is capable of taking the form of a foam by the mere fact of its composition and can also be defined as a self-foaming composition for topical application.
  • the present invention therefore, as a first object, a composition containing trifarotene intended for topical non-rinsed application in the form of a foam, advantageously of semi-solid consistency, advantageously not containing a foaming surfactant, and comprising a pharmaceutically compatible medium with a topical application not rinsed especially on the skin and superficial body growths.
  • composition in the form of a foam (also hereinafter referred to as self-foaming composition), is meant a composition of semi-solid consistency having an aerated form comparable to a foam.
  • the self-foaming composition according to the present invention comprises at least two compositions or intermediate formulas in variable proportions and in particular the following ingredients:
  • composition or intermediate formula A comprising an activating agent for the gas-generating agent described below;
  • composition or intermediate formula B comprising a gas generating agent.
  • each intermediate composition may have a viscosity.
  • the gas generated by the gas generating agent may be any physiologically compatible gas and allowing to obtain a foam, such as carbon dioxide (CO 2 ) or oxygen (0 2 ).
  • the gas generated from the gas generating agent is carbon dioxide (CO 2 ).
  • the gas concentration can vary, the amount of bubbles in the composition can vary and thus give a composition that can go from unventilated to very highly aerated.
  • the term "activating agent of the gas generating agent" means an ingredient which, by chemical reaction with the gas generating agent, releases a gas.
  • it is an acid / base reaction.
  • the self-foaming composition may be preferably in all forms ranging from aerated to a very expanded foam.
  • composition according to the invention is suitable for topical application and may further comprise a physiologically acceptable medium, that is to say a medium compatible with the skin and superficial body growths. It is preferably a pharmaceutically acceptable medium.
  • the composition may comprise any active agent capable of exhibiting an activity, which may be therapeutic.
  • active agents may be, among others, chosen from emollient agents, humectants, anti-radical agents, anti-inflammatory agents, vitamins, depigmenting agents, anti-acne agents, anti-seborrhics agents, anti-fungal agents, keratolytic agents, sunscreens, slimming agents, skin coloring agents.
  • the composition in the form of foam may have a pH of between 2 and 8, preferably between 4 and 8.
  • the present invention relates either to a single compartmentalized container (each compartment hosting an intermediate formula) and preferably comprising 2 or 3 compartments, or a kit comprising each intermediate formula stored independently of one another and physically separated.
  • the intermediate composition (or formula) A may be in the form of a solution, an emulsion (lotion, cream, cream without emulsifier, milk, fluid cream) or a gel.
  • This composition advantageously contains the activating agent of the gas-generating agent, preferably an acid in sufficient quantity (which can be present in the form of an acid buffer / acidic pH base) which may be by way of non-limiting example the citric acid / sodium citrate pair.
  • Formula B can be in the form of a solution, a gel, an emulsion (lotion, cream, cream without emulsifier, milk, fluid cream).
  • This composition advantageously contains in sufficient quantity a gas generating agent, which may in particular be sodium bicarbonate.
  • the subject of the invention is also a kit or a single multi-compartment container as defined above, allowing the extemporaneous preparation of a composition in the form of a foam according to the invention, comprising separately at least two intermediate formulas ( or intermediate compositions):
  • an intermediate formula A comprising at least one activating agent for the gas generating agent
  • an intermediate formula B comprising at least one gas generating agent
  • trifarotene is contained in the intermediate composition A.
  • the activating agent of the gas-generating agent (also referred to as "gas-activating agent”) is a compound which reacts with the gas generating agent by a chemical reaction (preferably an acid-base reaction) releasing a gas.
  • the acid / base buffer of said acid may be any acidic buffer / base of the weak acid such as, for example, a citric acid / sodium citrate buffer or a tartaric acid / sodium tartrate buffer.
  • the alpha-hydroxy acids which are weak acids preferably having a pKa of between 2 and 6 such as citric acid, tartaric acid, malic acid, lactic acid but also acid phosphoric acid and pyrophosphoric acid and their optionally partially salified salts such as disodium pyrophosphate or sodium dihydrogen phosphate also called monosodium phosphate.
  • the gas-activating agent is chosen from a tartaric acid / tartrate salt buffer (for example sodium tartrate); citric acid / sodium citrate buffer alone; phosphoric acid, monosodium phosphate, disodium pyrophosphate alone or as a mixture with a citric acid / sodium citrate buffer.
  • the gas-activating agent is a citric acid / sodium citrate buffer alone or in admixture with monosodium phosphate and / or disodium pyrophosphate.
  • the content of citric acid / sodium citrate is preferably less than or equal to 2.4% relative to the total weight of the intermediate composition A, so as to limit any risk. tingling.
  • the citric acid / sodium citrate buffer is used in admixture with disodium pyrophosphate or sodium dihydrogenphosphate.
  • said gas-activating agent may be present in the intermediate formula A in an amount ranging from 0.001% to 95% by weight relative to the total weight of the intermediate composition A.
  • gas generating agent any agent that has the property of generating a gas by chemical reaction.
  • the gas generated from the gas generating agent present in the intermediate composition B is preferably carbon dioxide or carbon dioxide (C0 2 ) , and more preferably carbon dioxide (C0 2 ).
  • the gas generating agent is preferably selected from sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate and mixtures thereof.
  • the intermediate formula B comprises a carbon dioxide generating agent which is particularly preferably sodium bicarbonate. Said gas generating agent may be present in the intermediate formula B in an amount ranging from 1% to 10%, preferably from 2% to 8% by weight relative to the weight of the intermediate composition B.
  • the intermediate formula A may have an acidic pH, advantageously between 1.0 and 6.0, and the intermediate formula B may have a basic pH, advantageously between 7 and 12.
  • one or more intermediate formula (s) comprises trifarotene, either as such or in salt form, in an amount corresponding to 0.00001 to 20% by weight of trifarotene in the form of acid (i.e., 3 "-tert-butyl-4 '- (2-hydroxyethoxy) -4" - pyrrolidin-1-yl [1,1', 3 ', 1 "] terphenyl -4-carboxylic) relative to the total weight of the total composition.
  • trifarotene in the form of acid (i.e., 3 "-tert-butyl-4 '- (2-hydroxyethoxy) -4" - pyrrolidin-1-yl [1,1', 3 ', 1 "] terphenyl -4-carboxylic) relative to the total weight of the total composition.
  • the total composition (mixture of the intermediate of formulation A with the intermediate of formulation B) contains trifarotene, as is or in the form of salt, in an amount corresponding to 0.00001% to 1% by weight. preferably from 0.0001 to 0.1% by weight and more preferably from 0.001 to 0.1% by weight of trifarotene in acid form, relative to the weight of the total composition.
  • total composition or “total formula” means the composition of the product in the form of foam after the mixing of said intermediate compositions.
  • the trifarotene is contained in the intermediate composition A which has a better compatibility with the active.
  • trifarotene may in certain cases have a lower compatibility with the ingredients constituting formula B, and especially with sodium bicarbonate.
  • the intermediate formula A may be in any galenic form compatible with the desired dosage form for the final composition obtained by mixing formula A with formula B.
  • Intermediate formula B can be in any galenic form compatible with the desired dosage form for the final composition obtained by mixing formula B with formula A.
  • Advantageously formula B can be a gel, a solution, a suspension, a emulsion (cream, cream without surfactant, milk lotion, fluid cream), preferably an emulsion.
  • one of the two intermediate formulas is in the form of a gel.
  • the other intermediate formula is not in gel form.
  • Each intermediate formula of the multi-compartment kit or container as defined above, according to the invention comprises a physiologically acceptable medium, carrying the compound (s), and chosen in such a way that the compounds are capable of reacting with each other. other for forming a self-foaming composition upon mixing of at least intermediate formulas A and B.
  • the gas-generating agent such as sodium bicarbonate
  • the gas-activating agent such as the acid
  • composition obtained after mixing at least the formulas A and B it may of course remain gas-activating agent and / or unreacted gas generating agent.
  • the kit or the single multi-compartment container according to the invention can be designed so that during the preparation of the composition according to the invention, the intermediate formulas A and B can be mixed in a ratio by weight AB ranging from 0.5 to 2, preferably from 0.5 to 1.5, more preferably close to 1 (that is to say from 0.9 to 1, 1), and even more preferably from 1.
  • the kit can be designed to simultaneously release doses (by weight) of intermediate compositions A and B which can be in a ratio by weight ranging from 2 doses of B for 1 dose of A to 2 doses of A for 1 dose of B, preferably 2 doses of B for 1 dose of A at 3 doses of A for 2 doses of B.
  • the kit is designed to simultaneously release 1 dose of weight of A and 1 dose by weight of B.
  • the kit may be in any form compatible with, on the one hand, a separate preservation of the intermediate formulas A and B and, on the other hand, the ability to realize the mixture extemporaneously. of A and B.
  • intermediate formulas A and B may be packaged in a housing with at least two separate compartments, each containing A or B.
  • the kit may be in the form of a syringe to at least two separate bodies, each provided with a piston, said two bodies containing the respective formulas A and B, and being designed to release simultaneously by exercise.
  • the invention also relates to a process for the preparation of a composition according to the invention, characterized in that to obtain the composition in the form of a foam, the mixture is mixed with extemporaneously an intermediate formula A and an intermediate formula B of the kit as defined above, in relative proportions by weight AB may range from 0.5 to 2, preferably from 0.5 to 1, 5 and more preferably from 1.
  • gas-generating agent preferably sodium bicarbonate
  • gas-activating agent preferably citric acid and / or disodium pyrophosphate and / or sodium dihydrogen phosphate or monosodium phosphate.
  • the ratio by weight of citric acid / sodium bicarbonate is advantageously between 0.1 and 2, preferably between 0.5 and 1, and very preferred equal to 0.7.
  • the ratio by weight of disodium pyrophosphate / sodium bicarbonate is between 0.5 and 5, preferably between 1 and 3, and very preferably is equal to 2.4.
  • the weight ratio of sodium dihydrogenphosphate mono sodium hydrate / bicarbonate is between 0.5 and 5, preferably between 1 and 3 and very preferably is equal to 2.
  • the combination citric acid / sodium citrate, disodium pyrophosphate or sodium dihydrogenphosphate and a gelling system compatible with the galenic form has made it possible to obtain a formula with very stable physicochemical properties and in which trifarotene is particularly stable. not generating any unpleasant sensation on the skin and allowing the release of gas and thus the creation of foam.
  • Example 2B below shows that the compositions according to the present invention have excellent physical and chemical stability.
  • a composition is considered physically stable when its organoleptic characteristics, pH, viscosity and homogeneity of trifarotene do not change with time under different temperature conditions: ambient temperature (RT, or TA) and 40 ° C.
  • the ambient temperature corresponds to a temperature ranging from 15 ° C. to 25 ° C.
  • a composition is considered chemically stable when the content of active ingredient that it contains does not change with time under the various temperature conditions (RT and 40 ° C.)
  • the composition is considered stable when the content of trifarotene (expressed by weight relative to the weight of the intermediate formula) measured by all known techniques including HPLC, is included in the specifications ranging from 90% to 1 10% .
  • composition according to the invention may also comprise one or more agents chosen from dispersing agents, stabilizing agents, preserving agents, fatty substances, thickeners, dyes, perfumes, surfactants, gelling agents, complexing agents, neutralizing agents, non-foaming emulsifiers, fillers, sequestering agents, reducing agents, odor masks, plasticizers, softening agents, moisturizing agents, pigments, clays, mineral fillers, mineral colloids, polymers, proteins, pearlescent agents, waxes, oils such as paraffins, silicones, fatty acids, solid esters of fatty alcohol or of fatty acids, gums, wetting agents.
  • Water-soluble dyes such as FD & C Blue 1 (of formula and liposoluble dyes such as Sudan Red III or Red Nil have the advantage of coloring one of the formulation intermediates. This coloration makes it possible to control the good mixture of the two formulation intermediates and to enhance the formation of the foam. This coloration is in particular presented in the examples and in FIG.
  • the intermediate composition A advantageously containing at least one gas-activating agent preferably contains at least one gelling agent and / or suspending agent.
  • Formulation A can contain high amounts of acid and electrolytes.
  • the viscosity and the suspensive power of these formulas are often hard to guarantee over time.
  • gelling agents and / or suspending agents that are resistant to both electrolytes and acidic pHs that can be used in compositions A according to the invention
  • ready-to-use mixtures such as Ammonium Acrylate / Acrylamide Copolymer & Polyisobutene & Polysorbate 20 mixture sold by Seppic under the name Sepiplus 265®, Acrylamide / Sodium Acryloyldimethyl Taurate Copolymer &
  • Isohexadecane & Polysorbate 80 sold by Seppic under the name Simulgel 600 PHA®, Polyacrylate-13 & Polyisobutene & Polysorbate 20 sold by Seppic under the name Sepiplus 400®, Acrylates / C 10-30 Alkyl Acrylate Crosspolymer sold by Lubrizol under the name names Pemulen TM TR-1 Polymeric Emulsifier and Pemulen TM TR-2 Polymeric Emulsifier polysaccharides with as non-limiting examples xanthan gum such as
  • Xantural180® sold by Kelco gellan gum sold under the name Kelcogel® by Kelco, Sclerotium Gum sold under the name Amigel® by Alban Muller industry, guar gum and its derivatives such as Hydroxypropyl Guar sold under the name Jaguar name HP-105® sold by Rodhia, cellulose and its derivatives such as microcrystalline cellulose and sodium carboxymethyl cellulose sold under the name Blanose CMC 7H4XF® by the company Hercules, hydroxypropylmethylcellulose, in particular the product sold under the name Methocel E4M® premium name by the company Dow Chemical or hydroxyethylcellulose, in particular, the product sold under the name of Natrosol HHX 250® by the company Aqualon, the family of aluminum magnesium silicates such as Veegum K®, Veegum Plus ® or the Veegum Ultra® sold by the company Vanderbilt, the bentonite sold under the name Polargel HV® family of modified starches such as modified potato starch sold
  • Polyvinyl Alcohol also known by the abbreviation PVA sold by Merck under the name POLYVINYL ALCOHOL 40-88®, Vegum K®, Simulgel 600 PHA® and Xantural 180®, will be used alone or in combination two by two or the three together
  • the gelling agent as described above may be used at preferential concentrations ranging from 0.001% to 15% and, more preferably, ranging from 0.15% to 5% by weight relative to the weight of the intermediate formula A.
  • acrylic acid polymers such as Acrylates / C 10-30 Alkyl Acrylate Crosspolymer such as so-called non-electrolyte sensitive carbomers, sold under the name Ultrez 20®, Ultrez 10®, Carbopol 1382® or Carbopol ETD2020NF®, AQUA SF1 ® sold by the company Lubrizol, the Ammonium Acrylate / Acrylamide Copolymer & Polyisobutene mix &
  • Polysorbate 20 sold by Seppic under the name Sepiplus 265®, Acrylamide / Sodium Acryloyldimethyl Taurate Copolymer & Isohexadecane & Polysorbate 80 sold by Seppic under the name Simulgel 600 PHA®, Polyacrylate-13 & Polyisobutene & Polysorbate 20 sold by Seppic under the name Sepiplus 400®, Acrylates / C 10-30 Alkyl Acrylate Crosspolymer sold by Lubrizol under the names Pemulen TM TR-1 Polymeric
  • Emulsifying and Pemulen TM TR-2 Polymeric Emulsifying polysaccharides with, by way of nonlimiting examples, xanthan gum such as Xantural180® sold by Kelco, gellan gum sold under the name Kelcogel® by Kelco , the Sclerotium Gum sold under the name Amigel® by Alban Muller industry, guar gum and its derivatives such as Hydroxypropyl Guar sold under the name Jaguar HP-105® sold by Rodhia, cellulose and its derivatives such as microcrystalline cellulose and carboxymethyl sodium cellulose sold under the name Blanose CMC 7H4XF® by the company Hercules, hydroxypropylmethylcellulose, in particular the product sold under the name Methocel E4M® premium by Dow Chemical or hydroxyethylcellulose, in particular, the product sold under the name of Natrosol HHX 250® by the company Aqualon, the family of aluminum magnesium silicates such as Veegum K®, Veegum Plus® or Veegum Ultra
  • the gelling agent as described above may be used at preferential concentrations ranging from 0.001% to 15% and, more preferably, ranging from 0.15% to 5% by weight relative to the weight of the intermediate formula B.
  • HUMECTANT AGENTS Among the humectants and / or emollients whose role is to moisturize the skin and to facilitate the application of the formulation, optional use is made, without this list being limiting, of compounds such as a polyol which is miscible with water.
  • water at ambient temperature especially chosen from polyols having in particular from 2 to 20 carbon atoms, preferably having from 2 to 10 carbon atoms, and preferably having from 2 to 6 carbon atoms, such as glycerol, glycol derivatives such as propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, dipropylene glycol, diethylene glycol and mixtures thereof, but also sugars (for example glucose, lactose), polyethylene glycol (PEG) (for example Lutrol E400®), urea, amino acids (for example serine, citrulline, arginine, asparagine, alanine).
  • polyols having in particular from 2 to 20 carbon atoms, preferably having from 2 to 10 carbon atoms, and preferably having from 2 to 6 carbon atoms, such as glycerol, glycol derivatives such as propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, diprop
  • a humectant and / or emollient preferred agent mention may be made of glycerin and propylene glycol.
  • the humectants may be used, alone or in combination, at preferential concentrations ranging from 0.001% to 30% and, more preferably, ranging from 0.01% to 10% by weight relative to the weight of the total formula.
  • chelating agents that may be mentioned as non-limiting examples are ethylene diamine tetraacetic acid (EDTA), diethylene triamine penta-acetic acid (DTPA) and ethylene diamine di (O-hydroxyphenyl) acid.
  • acetic acid) EDA
  • H EDTA hydroxy-2-ethylene diamine triacetic acid
  • EDDHMA ethyldiamine-di (O-hydroxy-p-methyl phenyl) acetic acid
  • EEDCHA ethylene diamine-di acid
  • EDTA ethylene diamine tetraacetic acid
  • Titriplex I II® it may be used at preferential concentrations ranging from 0.001% to 1% and, more preferably, from 0.05% to 0.1% by weight based on the weight of the total formula; EXCI PIENTS WITH ADDITIONAL PROPRIETES
  • composition according to the invention may contain one or more cosmetic active ingredients, such as, for example, allantoin with anti-irritant properties, dipotassium glycyrrhizate for these anti-inflammatory properties or dimethyl isosorbide for its pro-penetrating properties. or alternatively the healing alpha bisabolol, urea, lactic acid, salicylic acid, the constituents of a cerate or a cereal of gallien, those of a glycerol of starch for their moisturizing properties.
  • cosmetic active ingredients such as, for example, allantoin with anti-irritant properties, dipotassium glycyrrhizate for these anti-inflammatory properties or dimethyl isosorbide for its pro-penetrating properties.
  • Fillers and / or particles can be used to stabilize and boost the foam. Some of them have the particular property of being placed at the interface water / air and thus stabilize this interface.
  • fillers mention may be made of talc, metal oxides such as zinc oxide, TiO 2 T2000 titanium dioxide sold by Merck under the name Eusolex® T-2000, clays such as laponites, bentones or bentonites but also cellulose ethers such as Methocel® K100 LV marketed by DOW, silicas such as Aerosil® R972 sold by the company EVONI K or SILICE HDK® H 13L sold by WACKER they can be used at concentrations ranging from 0.01% to 10% by weight relative to the weight of the total formula.
  • composition according to the invention may also comprise a fatty phase.
  • This fatty phase may be present in one and / or the other of intermediate compositions A and B.
  • the fatty phase may comprise from 0% to 95% by weight relative to the weight of each intermediate formula.
  • the fatty phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.
  • mineral oil there may be mentioned, for example, paraffin oils of different viscosities such as Primol 352®, Marcol 82®, Marcol 152® sold by the company Esso.
  • sweet almond oil such as Prunus Amygdalus Dulcis (Sweet Almond) oil supplied by SICTIA, palm oil, soybean oil, sesame oil, sunflower oil, olive oil, apricot kernel oil and its esters such as Apricot Kernel Oil PEG-6 Ester (Labrafil M1944CS).
  • Sophiderm® As animal oil or their substitute of vegetable origin, mention may be made of lanolin, squalene, fish oil, with as derivative perhydrosqualene sold under the name Sophiderm® by Sophim.
  • esters such as cetearyl isononanoate such as the product sold under the name Cetiol SN PH® by Cognis France, isononyl isononanoate such as DUB ININ® sold by Stéarine Dubois, diisopropyl adipate such as the product sold under the name Crodamol DA® by Croda, isopropyl palmitate, such as the product sold under the name Crodamol IPP® by Croda, caprylic capric triglyceride such as Miglyol 812® sold by the company Univar.
  • Parleam® sold by Rossow, PPG-
  • Stearyl ether (Arlamol PS15 E) provided by CRODA, PPG-1 stearyl ether (Arlamol PS1 1E-LQ) supplied by GATTEFOSSE.
  • silicone oil there may be mentioned a dimethicone such as the product sold under the name Q7-9120 Silicone Fluid® with a viscosity of 20 to 12500 is by the company Dow Corning, a cyclomethicone such as the product sold under the name ST- Cyclomethicone 5NF® also by Dow Corning.
  • a dimethicone such as the product sold under the name Q7-9120 Silicone Fluid® with a viscosity of 20 to 12500 is by the company Dow Corning
  • a cyclomethicone such as the product sold under the name ST- Cyclomethicone 5NF® also by Dow Corning.
  • oils may be present, alone or in combination, at levels ranging from 0.5 to 50% by weight and preferably from 2 to 30% by weight, relative to the weight of the total composition.
  • composition according to the invention may also comprise solid fatty substances such as natural or synthetic waxes, fatty acids such as stearic acid, fatty alcohols such as Speziol C18® pharma or Speziol C16® sold by the company.
  • Cognis, and texture agents of the tribehenate type such as Compritol 888® sold by Gattefossé or hydrogenated castor oils such as Cutina HR® sold by Cognis or glyceryl stearate such as GELEOL® sold by Gattefossé or De 9045 Elastomer Blend® sold by Dow Corning.
  • non-liquid fatty substances may be used alone or as a mixture of 0 to 30% by weight relative to the weight of the total formula.
  • an exceptional foam quality has been observed when fatty alcohols of formula CH 3 (CH 2) n OH (n is between 11 and 23) are present at contents greater than 1% by weight relative to the weight of the total formula .
  • composition according to the invention may also comprise one or more nonionic emulsifiers.
  • hydrophilic emulsifiers of the Glyceryl Stearate (and) PEG-100 Stearate type sold under the name Arlacel 165FL® by the company Uniquema
  • the emulsifiers that can be used are the polyglycerol esters. These are polyglycerinated fatty acid esters obtained by condensation of glycerine. Glycolipidic emulsifiers such as Montanov 202® sold by the company SEPPIC. Some emulsifiers can be sold in the form of a mixture such as Emulium Kappa® and Emulium Delta® sold by Gattefosse. These emulsifiers can be used alone or in combination so that the HLB of the system is greater than 12 and preferably greater than 15. Such emulsifiers can be used between 0.01% and 30% by weight relative to the weight of the total composition. preferably between 0.1% and 15%, and more preferably between 0.5% and 7%.
  • PRESERVATIVES examples include benzalkonium chloride, bronopol, chlorhexidine, chlorocresol and its derivatives, ethyl alcohol, phenoxyethanol, potassium sorbate, diazolidinyl urea, alcohol benzyl, parabens, sodium benzoate or mixtures thereof.
  • Step 1 At a temperature above 60 ° C, add stirring the gelling agents to the main water phase.
  • Step 2 With stirring introduce trifarotene in an annex phase
  • Step 3 (optional): At the same time melt the fat phase at a temperature above 60 ° C.
  • This fatty phase is composed of emulsifiers, waxes, emollient oils
  • Step 4 At a temperature above 60 ° C make the emulsion by adding the fat phase to the main phase.
  • Step 4 Add the annex phase containing trifarotene in the main phase
  • Step 5 Cool and add additives such as dye, cosmetic actives, humectants.
  • additives such as dye, cosmetic actives, humectants.
  • the amounts are expressed in relation to the weight of the intermediate formula and not to the weight of the total formula.
  • PROPYLENE GLYCOL 4.0 Formulas B: Intermediate compositions B containing the gas generating agent:
  • Step 1 ' At a temperature above 60 ° C, add stirring the gelling agents to the main water phase.
  • Step 2 Optional: At the same time heat the fatty phase (containing oils, waxes, and surfactants) to a temperature above 60 ° C.
  • Step 3 Optional: At a temperature above 60 ° C make the emulsion by adding the fat phase to the main phase.
  • Step 4 Add additives such as preservatives or ethanol at a temperature suitable for the additive.
  • Step 5 ' Neutralize the mixture.
  • Step 6 ' At a temperature below 40 ° C add sodium bicarbonate
  • the table below represents the mixtures in a 1: 1 weight ratio of the intermediate compositions A and B described above.
  • a cross at the intersection of two intermediates formulation indicates that the mixture was tested and generated a foam with the desired properties.
  • Density formula A5 placebo, that is to say without trifarotene (but with blue dye) 1 .108
  • the measurement of the density of the foam shows that the volume has been increased by a factor of 4 and confirmed by the photos in Figure 1.
  • the photo on the left represents the moment of mixing (T0) and the photo on the right represents the foam obtained when the acid / base chemical reaction is complete.
  • the study is carried out according to the current TG439 OECD protocol for the short application time (contact time RHE / product 15min). This protocol is suitable for a long application time (contact time RHE / product 18h).
  • the objective of this study is to evaluate the tolerance of the supports of complete and intermediate formulas on reconstructed human epidermis (RHE, Episkin model) through:
  • the tested formulas are:
  • An intermediate composition of acid formulation A7 example placebo (that is to say, not containing trifarotene),
  • Measurements of MTT according to the current OECD protocol indicate that all formulas tested are non-irritating.
  • the assay of I L-1a of the complete formula according to the invention after a short time and a long time of exposure shows a lower level of irritation markers after application of the commercial reference.
  • EXAMPLE 4 The ideal content of citric acid, sodium pyrophosphate and sodium dihydrogenphosphate monohydrate was established empirically to react with 5% sodium bicarbonate. The values are expressed in percent weight / weight with respect to the weight of each of the two intermediate formulas.
  • citric acid / sodium citrate buffer can advantageously be substituted with disodium pyrophosphate and vice versa, as the contents cited by way of example in the table below:
  • Table III the values are expressed in weight / weight percentage with respect to the weight of each of the two intermediate formulas
  • citric acid / sodium citrate buffer may advantageously be substituted with sodium dihydrogen phosphate monohydrate and vice versa, as the contents cited by way of example in Table IV below:
  • Table IV The values are expressed as a weight / weight percentage relative to the weight of each of the two intermediate formulas
  • the amount of citric acid is greater than or equal to 1, 4, the amount of foam is optimal when the disodium pyrophosphate is present in the composition according to the following equation:
  • the purpose of this study is to evaluate the penetration and distribution of different formulations according to the invention in human skin.
  • trifarotene is measured in: the unabsorbed fraction, the stratum corneum, the epidermis, the dermis and the receiving liquid.
  • the tested formulas are:
  • the scattering cells used are static diffusion cells, based on Franz model diffusion cell, with the following characteristics:
  • the receiving compartment is surrounded by a water jacket heated to 37 ° C ⁇ 1 ° C, ensuring a temperature of 32 ° C ⁇ 1 ° C on the surface of the skin.
  • the receptor compartment is separated from the donor compartment by the skin membrane, the epidermal face being on the donor side.
  • the Receiver compartment containing a magnetic stirring bar was filled with the receiving fluid so as to prevent any formation of air bubbles. During the diffusion time, the receiving fluid was stirred continuously to ensure homogenization Preparation of skin samples:
  • Skin samples from donors aged 42, 44 and 69 years were mounted on the diffusion cell with PBS as the receiving fluid.
  • the average skin thickness was 0.89 ⁇ 0.07 mm with a maximum of 1.39 mm and a minimum of 0.45 mm. Thicknesses of all specimens.
  • TEWL trans-epidermal water-insensitive loss
  • the penetration of the chemical foam formulations is significantly different from the cream reference (according to the example A4 + B7 in a 50:50 mixture), as illustrated in FIG.
  • the chemical foam formulations penetrate less than the cream reference (according to the example A4 + B7 in a 50:50 mixture), as illustrated in FIG. 3. None of the receiving fluid samples was quantifiable whatever the formulation tested; which suggests low systemic exposure.
  • the present study confirms the obtaining of a foam which remains on the surface of the skin, in order to avoid undesirable effects such as irritation especially on young skin and to allow the keratolytic effect of trifarotene; thus to obtain a foam adapted to the treatment of ichthyosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16775633.7A 2015-09-29 2016-09-27 Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose Withdrawn EP3355859A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559201A FR3041535B1 (fr) 2015-09-29 2015-09-29 Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
PCT/EP2016/073014 WO2017055297A1 (fr) 2015-09-29 2016-09-27 Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose

Publications (1)

Publication Number Publication Date
EP3355859A1 true EP3355859A1 (fr) 2018-08-08

Family

ID=54848734

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16775633.7A Withdrawn EP3355859A1 (fr) 2015-09-29 2016-09-27 Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose

Country Status (9)

Country Link
US (1) US11020348B2 (es)
EP (1) EP3355859A1 (es)
JP (1) JP2018529773A (es)
KR (1) KR20180057713A (es)
CN (1) CN108289838A (es)
AU (1) AU2016330790B2 (es)
FR (1) FR3041535B1 (es)
MX (1) MX2018003640A (es)
WO (1) WO2017055297A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
CA2309380C (en) 1997-11-07 2007-11-27 Medion Research Laboratories Inc. Viscous compositions containing carbon dioxide
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6177092B1 (en) 1998-11-10 2001-01-23 Color Access, Inc. Self-foaming cleansing systems
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
FR2830415B1 (fr) 2001-10-09 2004-07-09 Rhodia Chimie Sa Utilisation d'une composition a base de gomme xanthane en tant que stabilisant de mousses molles, et les mousses a base de cette composition
CA2502986C (en) * 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US20050123487A1 (en) 2003-12-08 2005-06-09 Spadini Alessandro L. Stable nonaqueous liquid reactive skin care and cleansing packaged product
US20060057075A1 (en) 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
PT1791791T (pt) 2004-09-27 2019-09-12 Special Water Patents B V Métodos e composições para tratamento de água
KR101368107B1 (ko) 2006-03-31 2014-03-14 스티펠 리서치 오스트레일리아 피티와이 리미티드 발포성 현탁겔
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
FR2924944A1 (fr) 2007-12-18 2009-06-19 Galderma Sa Composition a base d'une avermectine et du soufre ou d'un derive du soufre, notamment pour le traitement de la rosacee
US10589134B2 (en) 2008-01-30 2020-03-17 Kimberly-Clark Worldwide, Inc. Hand health and hygiene system for hand health and infection control
DE102008029357A1 (de) 2008-06-20 2009-12-24 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Schäumende kosmetische Zubereitung
JP2012516320A (ja) 2009-01-30 2012-07-19 イッスム リサーチ デベロプメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム リミテッド 爪および皮膚を処置するための組成物
FR2943914A1 (fr) * 2009-04-06 2010-10-08 Fabre Pierre Dermo Cosmetique Flacon mousseur comprenant une composition pharmaceutique
EP2429503A1 (en) 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20110236503A1 (en) 2010-03-23 2011-09-29 Cosmalabs International, Llc Topical Skincare Composition
AU2011273510B2 (en) 2010-06-30 2015-04-16 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
EP2620138B1 (en) 2010-09-24 2016-12-07 Daido Chemical Corporation Foam-type external skin preparation
FR2969492B1 (fr) 2010-12-23 2013-07-05 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene
FR2969493B1 (fr) 2010-12-23 2013-07-05 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo
FR2969491B1 (fr) 2010-12-23 2013-07-12 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo
US9301935B2 (en) 2013-06-10 2016-04-05 Naeem Uddin Broad spectrum pharmacological composition for treatment of various infections and diseases and methods of use
EP3010487A4 (en) 2013-06-17 2016-12-07 Contract Pharmaceuticals Ltd NON-AEROSOL FOAM FOR TOPICAL ADMINISTRATION
CN105939704A (zh) * 2013-12-04 2016-09-14 盖尔德马研究及发展公司 优选包含类维生素a的脂质微胶囊以及含有其的组合物、制造其的方法及其在皮肤病学中的用途
BR112016022293A2 (pt) 2014-03-28 2017-08-15 Galderma Res & Dev Composição que contém peróxido de benzoíla, uso cosmético de uma composição, medicamento destinado a uma aplicação tópica sobre a pele, kit e processo de preparação de uma composição autoespumante
BR112016022340A2 (pt) 2014-03-28 2017-08-15 Galderma Res & Dev Composição, uso cosmético de uma composição, medicamento e kit
CN104382863B (zh) 2014-11-29 2017-07-07 河南后羿实业集团有限公司 一种禽用伊维菌素泡腾颗粒
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.

Also Published As

Publication number Publication date
WO2017055297A1 (fr) 2017-04-06
AU2016330790B2 (en) 2022-05-12
FR3041535B1 (fr) 2019-01-25
CN108289838A (zh) 2018-07-17
KR20180057713A (ko) 2018-05-30
JP2018529773A (ja) 2018-10-11
US11020348B2 (en) 2021-06-01
MX2018003640A (es) 2018-04-30
AU2016330790A1 (en) 2018-05-10
FR3041535A1 (fr) 2017-03-31
US20180280298A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
EP3122325B1 (fr) Mousse chimique non rincée contenant du peroxyde de benzoyle
EP3122324B1 (fr) Mousse chimique rincée contenant du peroxyde de benzoyle
EP3355869B1 (fr) Composition nettoyante auto-moussante à rincer, contenant de l'ivermectine
EP3355857A1 (fr) Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'acné
WO2017055297A1 (fr) Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose
EP3355868B1 (fr) Mousse chimique non rincée contenant du propionate de clobétasol, et son utilisation dans le traitement du psoriasis
EP3122322B1 (fr) Mousse chimique non rincée contenant de l'adapalene et du peroxyde de benzoyle
EP3355858B1 (fr) Mousse chimique non rincée contenant de la brimonidine et son utilisation dans le traitement de la rosacée
EP3355866B1 (fr) Composition nettoyante auto-moussante contenant du propionate de clobétasol, et son utilisation dans le traitement du psoriasis
EP3355867B1 (fr) Mousse chimique non rincée comprenant de l'ivermectine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230902